Oncotelic details 2023 pipeline: 10+ OT-101 trials, pancreatic & glioma FPI, BARDA award

Oncotelic Therapeutics, Inc.

At least 10 investigator-initiated OT-101 trials planned in 2023 for NSCLC, pancreatic, melanoma, gliomas.
Phase 2/3 pancreatic cancer trial expected FPI 2023; 55% long-term disease control in prior P001 study.
BARDA awarded maximum EZ-BAA funding for OT-101 long COVID; observational trial starts 2023.
Subsidiary Pet2DAO to launch PDAO token and distribute to shareholders/stakeholders in 2023.
R&D costs reduced >95%, G&A >50% per latest 10Q; new CMO and CRO added.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.